Electromed

ELMD · NYSE American

$27.44+$0.04 (+0.15%)TodayMarket closed · Oct 20, 8:00 PM ET

Prev close $27.40

ELMD analyst rating

BuyConsensus of 3 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy3
Hold0
Underperform0
Sell0

12-month price target · 4 analysts

Average $49.47 (+80.3% upside)

Low: $47.47
Now: $27.44
High: $52.50

Upgrades and downgrades

The latest rating actions, newest first

ELMD analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Lake Street	Aug 26, 2026	Maintains	Buy	$36.00 → $47.00	33%
B. Riley Securities	May 13, 2026	Maintains	Buy	$38.00 → $40.00	48%
Freedom Broker	Feb 12, 2026	Maintains	Buy	$34.00 → $36.00	45%
Freedom Broker	Nov 19, 2025	Maintains	Buy	$31.00 → $34.00	45%
Roth Capital	Nov 13, 2025	Maintains	Buy	$35.00 → $36.00	48%

The case for and against

Updated Jan 12, 2026

Bull case

Electromed Inc. reported a substantial growth in homecare revenue, which increased by 14.8%, reaching $14.1 million, driven by enhanced sales rep productivity and effective demand generation strategies. The company demonstrated significant expansion in its market presence, with notable increases in distributor sales by 41% and hospital sales by 52%, indicating robust demand for its airway clearance products. Furthermore, the rise in SG&A expenses by 17.2% reflects Electromed's strategic investments in scaling its operations, positioning the company well for continued growth in the homecare and acute care sectors.

Bear case

Electromed Inc. faces a challenging financial outlook due to several fundamental issues, including margin compression, increasing competitive pressures, and diminished sales representative productivity, which may hinder revenue growth. Additionally, potential delays in the company's growth drivers for Pain Management and Wound Care could further adversely impact expected growth rates and profit margins. The significant decline in stock value from a recent peak of $35.43 to approximately $18 underscores investor concerns about the company's ability to navigate these obstacles effectively.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.